SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after its Q2 earnings report vastly exceeded expectations and significantly boosted its full-year revenue outlook, fueling community discussions around its undervaluation and potential for a short squeeze despite ongoing margin concerns.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is a top trend as strong Q4 earnings and robust data center growth clash with a significant after-hours sell-off. The community is sharply divided, with bulls highlighting conservative guidance and market manipulation, while bears point to already high valuations and unmet "blowout" AI expectations.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending due to its recent earnings report, which revealed missed estimates and slowing branded checkout growth, intensified by an unexpected CEO transition and conservative forward guidance. This has ignited a strong debate within the community, with many expressing extreme pessimism, while others see a deep value opportunity in the heavily discounted shares.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is rallying significantly after delivering strong earnings that exceeded expectations, sparking community optimism for a major turnaround and potential short squeeze. Conversations highlight the ongoing strength of the solar-plus-storage narrative and recent product innovations like advanced microinverters and EV charging solutions.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet (GOOG) is trending fiercely ahead of its imminent earnings report, driving intense community discussion around its AI leadership, especially Gemini's growth and its implications for cloud and ad revenues. Additionally, Waymo's surging valuation and expansion are gaining attention, despite ongoing regulatory scrutiny, with many debating its potential to surpass rivals in market valuation.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as it approaches its earnings report with the stock trading near multi-year lows following a prolonged sell-off. Community sentiment is sharply divided, with many criticizing the CEO and profitability concerns amidst talks of global age restrictions for social media, while others see a massive buying opportunity given the platform's large user base and potential for subscription monetization.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is a major talking point after unexpectedly lowering its 2026 guidance, citing U.S. pricing pressure and increased competition, which led to a notable stock dip. While many in the community view this as an overreaction and a prime buying opportunity, pointing to strong early oral Wegovy sales and a new share repurchase program, others are concerned about management's communication and the intensified market landscape.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing intense discussion amid extreme oversold conditions and record trading volumes, with many investors viewing it as a capitulation bottom and a historic buying opportunity for the software sector despite ongoing community debates about AI's disruptive impact.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is the subject of intense investor conversation, grappling with concerns over its premium valuation and market reactions to guidance, even as its foundational technology is critical for advancing AI, robotics, and data center compute. The community is deeply split, with many highlighting its expanding "Physical AI" division and strategic position, while others remain skeptical about its near-term execution and market performance.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

Amidst a protracted sell-off, UiPath is actively debated as investors grapple with its steep decline, attributed by some to broader software sector weakness and persistent insider selling, while others contend it presents an undervalued opportunity as a leader in Agentic AI orchestration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief...

HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual...

Credit-Card Sized Device Wins FDA Clearance for At-Home Heart Monitoring

Cardiac care is undergoing a fundamental shift as technology enables patients to capture critical health data outside traditional medical settings. The ability to record meaningful cardiac information during symptomatic episodes, rather than hours or days later in a doctor's office, represents a paradigm change in how physicians diagnose and manage heart conditions affecting millions of Americans.Shares of HeartBeam, Inc. (NASDAQ: BEAT) are surging Wednesday after the company announced FDA 510(k) clearance for its groundbreaking 12-lead electrocardiogram (ECG) synthesis software for ...

<ul class="summary-bullets"><li>The clearance enables HeartBeam’s cable-free technology to capture the heart’s electrical signals in three dimensions.</li><li>The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination.</li><li>The company intends to roll out a controlled commercial launch in early 2026.</li></ul>HeartBeam, Inc. (BEAT) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has cleared its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment, which enables its cable-free technology to capture the heart’s electrical signals in three dimensions and convert them into a complete 12-lead ECG.The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination, marking a significant milestone for the company.<h2 class="st-heading-2">Why It Matters?</h2>Unlike traditional single-lead or 6-lead devices, this innovation allows patients to obtain accurate cardiac readings from home, with synthesized results promptly reviewed by board-certified cardiologists.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/BEAT">HeartBeam’s stock</a> traded over 72% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day, while message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<blockquote>“We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening and prediction algorithms trained on our unique longitudinal data.”-Robert Eno, CEO, HeartBeam</blockquote><h2 class="st-heading-2">Limited U.S. Launch Planned</h2>The company intends to roll out a controlled commercial launch in early 2026, targeting select concierge and preventive cardiology groups that have expressed strong interest.&nbsp;It has developed a working prototype of an extended-wear 12-lead ECG patch, designed to provide continuous cardiac monitoring. As HeartBeam’s 3D ECG platform adoption grows, the resulting data repository will enable longitudinal analysis. The company plans to use this data to develop AI-based screening and predictive algorithms.BEAT stock has lost over 64% in 2025 and over 73% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-signals-tough-road-ahead-amid-slumping-ev-demand-ceo-says-there-is-a-slowdown-there-s-no-question-about-it/cLIHRZWRENx">Lucid Signals Tough Road Ahead Amid Slumping EV Demand: CEO Says ‘There Is A Slowdown, There’s No Question About It’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Atrial tachycardia electrocardiogram, heart rhythm disorder where the patient complains of rapid palpitation sensations.

Why Did BEAT Stock Rocket 72% In Pre-Market Today? 

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.

Equity

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.


What's Behind HeartBeam's Over 40% After-Hours Surge?

HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.read more...

HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following...

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

HeartBeam Reports Third Quarter 2025 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for...

HeartBeam Earnings Preview

HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13...

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

HeartBeam Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $GOOGL earnings on Wednesday?

Current Price	$1.44
Prev Close	$1.45
Open	$1.44
Dividend Yield	0.00%
50-Day Moving Average	$1.88
Beta	1.17
Avg. Volume	1.19M
PE Ratio	-2.17

52-Week High	$4.00
52-Week Low	$0.54
Market Capitalization	$49.94M
EPS (Annual)	-$0.7299
Price to Book	121.83
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Latest BEAT News

BEATHeartBeam Inc